Eisai Co (MEX:4523N) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:4523N Eisai Co Ltd MEX:4523N
77 GF Score
Price MXN888.98
GF Value MXN1,078.35
! 8 Warning Signs
View Full Analysis

What is Eisai Co FFO?

FFO (Funds from operations) only applies to REITs.

MEX:4523N
77GF Score
Eisai Co Ltd MEX:4523N
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eisai Co (MEX:4523N) Overvalued in 2026?

Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued. The current stock price of MXN888.98 is trading 17.6% below its estimated GF Value™ of MXN1,078.35.

Key valuation signals for MEX:4523N:

  • FFO:
  • GF Value™: MXN1,078.35 vs. price of MXN888.98 (17.6% below fair value)
  • GF Score™: 77/100 with 8 warning signs

No single metric tells the full story. See the MEX:4523N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eisai Co Business Description

Address 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
77GF Score

Get the complete analysis for MEX:4523N

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN888.98
Price
MXN1,078.35
GF Value